Novartis’ meningitis B vaccine,
Bexsero, has received Breakthrough
Therapy designation in the United
States from the Food and Drug
Administration (FDA).
The designation means the FDA
would expedite the development
and review of the drug, the
organisation said.
Novartis said it could be applying
for US licensure of the drug in the
second quarter of this year, with
timing depending upon the FDA
guidance.
Novartis’ vaccine has been
recommended for inclusion on
the UK’s National Immunisation
Program (PD 25 Mar) and has been
on sale in Australia through private
prescription since early March (PD
07 Mar).The above article was sent to subscribers in Pharmacy Daily's issue from 09 Apr 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Apr 14
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.